Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/breastcancer.2.010
Oncologist well-being in the era of COVID-19: A call to action
Anna Chichura1,2,*, Katherine Yao1,2
- 1Department of Surgery, NorthShore University Health System, Evanston Hospital, Evanston, IL, USA
- 2University of Chicago, Pritzker School of Medicine, Chicago, IL, USA
Corresponding Author
Anna Chichura, Anna.Chichura@uchospitals.edu
Received Date: November 22, 2021
Accepted Date: January 20, 2022
Chichura A, Yao K. Oncologist well-being in the era of COVID-19: A call to action. J Breast Cancer Res. 2022;2(1):1-3.
Copyright: © 2022 Chichura A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Significance of BRCA genetic testing for preoperative breast cancer patients
Examining BRCA mutations in preoperative breast cancer patients is very important when selecting a surgical procedure. Although there are advantages and disadvantages associated with knowing about the presence of genetic mutations, including for the patient’s family, there are many benefits for the patient. BRCA genetic testing should be recommended for patients who are strongly suspected of being positive for a BRCA mutation.
BRCA1 and BRCA2 mutation variants in early breast cancer confer added prognostic information
Metastatic breast cancer to brain carries poor prognostic features with increased risks of occurrence in Tripple- negative and HER- positive breast tumors. In addition, tumors with mutated BRCA tumors, carry as well increased metastatic incidence. However, new clinical evidence suggest distinct clinical features between BRCA1 or BRCA2 mutated breast cancer and brain metastasis. Review of literature may help characterize the distinctive differences between BRCA1 or BRCA2 breast tumors and subsequent metastasis to brain.
The role of MRI in detecting and characterizing brain metastases from breast cancer
Brain metastases are a feared complication of breast cancer, occurring in 15-25% of patients and being associated with poor prognosis and reduced quality of life. Magnetic resonance imaging (MRI) is an advanced technique that uses powerful magnetic fields and radio waves to produce detailed three-dimensional (3D) images of the brain's neuroanatomy and any potential pathology, especially in the management of brain metastases. The review article by Mohammadi et al. provides a timely and comprehensive overview of the utility of MRI for detecting and characterizing brain metastases from breast cancer.
Identification and validation of N7-methylguanosine-associated gene NCBP1 as prognostic and Prognostic immune-associated biomarkers in breast cancer patients
Epigenetics is the study of heritable modifications to gene expression, such as DNA methylation, histone modifications, and RNA modifications, that do not alter the nucleotide sequence of the corresponding gene. Recently, RNA modification has emerged as a novel research focus. We have detected over 170 different RNA modifications, such as N6-methyladenosine (m6A), N7-methylguanosine (m7G), 5-methylcytosine (m5C), N1-methyladenosine (m1A), N3-methylcytosine (m3C), and pseudouridine (ψ).These modifications are important for biological processes like RNA metabolism and post-transcriptional regulation.
Cancer-related anxiety, COVID-19, and the oncologist: the formation of a ‘Balint’ process group
The management of anxiety and distress in patients with cancer is stressful for the oncology clinicians who treat them. Unfortunately, psychosocial care for patients with cancer is not universally available or standardized. Referrals from oncology services to psychological serves are often not initiated early enough, may not be encouraged from medicine or surgical services, and are subsequently foregone or patients do not follow up beyond a single appointment.